Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Following a Type D meeting with the United States Food and Drug Administration (FDA), Amplia Therapeutics has received feedback on proposed modifications to our US clinical trial protocol for narmafotinib, our best-in-class FAK inhibitor. The trial will study narmafotinib in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients.

A Type D meeting is an opportunity for a company to seek feedback from the FDA for specific questions regarding clinical development activities.

In the written response received by the Company, the FDA noted that the proposed changes ‘appear reasonable’ clearing the way for the Company to finalise the study protocol and initiate the final stages of trial planning prior to commencing the study.

Amplia CEO and MD Dr Chris Burns commented:  
 
“We are grateful for the thoughtful input from the FDA regarding the modifications to our clinical trial protocol. These changes will allow the Company to progress the trial in a more time-efficient and capital-efficient manner, and we are now in the final planning stages to start the trial in the coming months.”

Click link below to read the full ASX Release.

Type D Meeting Outcome with US Food and Drug Administration